SMMT

Summit TherapeuticsF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$24.00

+61.5% vs current

Most likely

Base case

45%

Probability

Target price

$15.00

+0.9% vs current

B-

Bear case

25%

Probability

Target price

$9.00

-39.4% vs current

AI sentiment snapshot

Latest data as of 2026-05-04

AI commentary

Headline flow is active and mostly company-driven, but the tone still looks more like milestone monitoring than thesis confirmation. The April 30 update preserved major catalysts yet did not deliver a decisive de-risking event, and the May 1 anchor close of $16.115 still sits far below the packet's median analyst target. Deterministic priors remain negative across 5-, 20-, 60-, and 120-day horizons despite strong evidence quality, so the setup stays cautious until ASCO and later Phase III/FDA checkpoints resolve.

RankAlpha Sentiment Codex - 2026-05-04

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators

Impact

tentative

Confidence

AI events

2026-05-31catalystASCO plenary overall-survival data from HARMONi-6High impact

Summit said overall-survival data from Akeso-sponsored Phase III HARMONi-6 will be presented as a late-breaking plenary at ASCO on May 31, 2026, creating a near-term readthrough for ivonescimab efficacy in first-line squamous NSCLC even though the study was run in China and generated by Akeso [#8-K-2026-04-30].

2026-07-15catalystMid-2026 expansion of combination and Phase III development breadthHigh impact

Summit said the initial GSK-combination study is expected to begin dosing patients in mid-2026, ILLUMINE enrollment is expected to begin in Q2 2026, and the RevMed collaboration already began enrolling in Q1 2026; these milestones broaden the ivonescimab platform story but are still support points rather than decisive value inflections [#8-K-2026-04-30].

2026-09-30eventHARMONi-3 squamous final PFS in 2H 2026 after interim continuationHigh impact

The April 30 update said the Independent Data Monitoring Committee recommended HARMONi-3 squamous continue as planned at the interim PFS look, with no safety concerns noted and final PFS data still expected in the second half of 2026; that keeps the program alive but removes the possibility that the interim itself would be the de-risking event [#8-K-2026-04-30].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-04 • Updated nightlySource: Internal modelMethodology